David D. Kim, PhD, is an Assistant Professor of Medicine and Public Health Sciences at the University of Chicago. Previously, he served as an Assistant Professor and Program Director of the Cost-Effectiveness Analysis Registry at the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center. As a health economist, Dr. Kim's primary focus centers around measuring the value of health interventions and providing guidance for value-based health care decisions. His extensive research encompasses three key areas: (1) evaluating long-term health, equity, and economic impact of health interventions using simulation modeling; (2) measuring the use and consequences of low-value care; (3) enhancing methodology in economic evaluation and research prioritization. He has written several pieces highlighting the gap between guideline recommendations and actual practice in cost-effectiveness analysis with future directions for improvement. Recognizing the need for reliable tools to facilitate value-based decision-making, he has developed a formal quality assessment tool for cost-effectiveness analysis, called the Criteria for Health Economic Quality Evaluation (CHEQUE) tool. He has also created a decision framework and checklist to assess the transferability of economic evaluations. Dr. Kim received his PhD in Health Economics from the University of Washington and holds a Master's degree in Biostatistics from the University of Michigan.
University of Washington
Seattle
PhD - Health Economics
2016
University of Michigan
Ann Arbor
MS - Biostatistics
2012
University of Michigan
Ann Arbor
BSE - Biomedical Engineering
2009
Patient-Provider Communication and Access, Use, and Financial Burden of Care.
Patient-Provider Communication and Access, Use, and Financial Burden of Care. Am J Prev Med. 2024 Jul 28.
PMID: 39002888
Out-of-pocket costs for diagnostic testing following abnormal prostate cancer screening among privately insured men.
Out-of-pocket costs for diagnostic testing following abnormal prostate cancer screening among privately insured men. Cancer. 2024 Oct 01; 130(19):3305-3310.
PMID: 39005006
Balancing innovation and affordability in anti-obesity medications: the role of an alternative weight-maintenance program.
Balancing innovation and affordability in anti-obesity medications: the role of an alternative weight-maintenance program. Health Aff Sch. 2024 Jun; 2(6):qxae055.
PMID: 38828004
A systematic review and meta-analysis of synthetic cathinone use and psychosis.
A systematic review and meta-analysis of synthetic cathinone use and psychosis. Psychopharmacology (Berl). 2024 Mar 06.
PMID: 38446172
The role of simulation modelling in public health policy evaluation.
The role of simulation modelling in public health policy evaluation. Lancet Public Health. 2024 Mar; 9(3):e150-e151.
PMID: 38429013
Telemedicine-Based Cognitive Examinations During COVID-19 and Beyond: Perspective of the Massachusetts General Hospital Behavioral Neurology & Neuropsychiatry Group.
Telemedicine-Based Cognitive Examinations During COVID-19 and Beyond: Perspective of the Massachusetts General Hospital Behavioral Neurology & Neuropsychiatry Group. J Neuropsychiatry Clin Neurosci. 2023 Dec 19; appineuropsych20220154.
PMID: 38111331
Development and Validation of the US Diabetes, Obesity, Cardiovascular Disease Microsimulation (DOC-M) Model: Health Disparity and Economic Impact Model.
Development and Validation of the US Diabetes, Obesity, Cardiovascular Disease Microsimulation (DOC-M) Model: Health Disparity and Economic Impact Model. Med Decis Making. 2023 Oct-Nov; 43(7-8):930-948.
PMID: 37842820
Health and Economic Impacts of Implementing Produce Prescription Programs for Diabetes in the United States: A Microsimulation Study.
Health and Economic Impacts of Implementing Produce Prescription Programs for Diabetes in the United States: A Microsimulation Study. J Am Heart Assoc. 2023 08; 12(15):e029215.
PMID: 37417296
Author Reply.
Author Reply. Value Health. 2023 Oct; 26(10):1578-1579.
PMID: 37419319
Accounting for Nonhealth and Future Costs in Cost-Effectiveness Analysis: Distributional Impacts of a US Cancer Prevention Strategy.
Accounting for Nonhealth and Future Costs in Cost-Effectiveness Analysis: Distributional Impacts of a US Cancer Prevention Strategy. Pharmacoeconomics. 2023 09; 41(9):1151-1164.
PMID: 37195368